SuperNova Diagnostics® Secures European Partnership with Concile, GmbH
Under terms of the agreement, SuperNova will develop and manufacture the point-of-care test product, secure regulatory approvals and co-promote the product in the European market. SuperNova will receive upfront payments, milestone development payments and a revenue-sharing sales deal for all sales in the European Union (EU). SuperNova will retain 100 percent of marketing rights outside of the EU and has the ability to sub-license or sell directly. Other terms of the deal were not disclosed.
Franz Maier, Managing Director of Concile, said, "SuperNova's technology is a perfect fit to our specially diagnostics business in Europe, and we look forward to adding additional tests to the partnership over the coming year."
Neil J. Campbell, President & CEO of SuperNova, commented, "The partnership and sales reach of Concile gives us a focused entry into the European market with an established leader and also allows us to build our commercial business into other markets."